At a glance
- Originator Bayer Schering Pharma; Freie Universitat Berlin
- Class Antiplatelets
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary thrombosis; Thrombosis
Most Recent Events
- 15 Jun 2004 Discontinued - Preclinical for Coronary thrombosis in Germany (unspecified route)
- 15 Jun 2004 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
- 09 Oct 2001 No-Development-Reported for Coronary thrombosis in Germany (Unknown route)